Compare EXG & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXG | FOLD |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | N/A | 2007 |
| Metric | EXG | FOLD |
|---|---|---|
| Price | $9.30 | $9.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $30.29 |
| AVG Volume (30 Days) | 533.2K | ★ 4.5M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 8.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $598,704,000.00 |
| Revenue This Year | N/A | $21.12 |
| Revenue Next Year | N/A | $21.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.28 |
| 52 Week Low | $6.78 | $5.51 |
| 52 Week High | $8.15 | $10.57 |
| Indicator | EXG | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 58.49 | 65.69 |
| Support Level | $9.14 | $9.63 |
| Resistance Level | $9.31 | $10.05 |
| Average True Range (ATR) | 0.12 | 0.37 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 90.68 | 54.40 |
Eaton Vance Tax-Mgd Glbl Div Eq Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary focus of the fund is capital appreciation. It invests in a diversified portfolio of domestic and foreign common stocks, emphasizing dividend-paying stocks. It writes call options on one or more U.S. and foreign indices for a portion of the value of its common stock portfolio to generate current cash flow from the options premium received. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, consumable fuels, and other sectors.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.